XW0Q316Introduction of Eladocagene exuparvovec into Cranial Cavity and Brain, Percutaneous Approach, New Technology Group 6
- Billable / Specific Code
XW0Q316 is a billable ICD-10-PCS procedure code for Introduction of Eladocagene exuparvovec into Cranial Cavity and Brain, Percutaneous Approach, New Technology Group 6. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRGs 628, 629, 630. The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.
Code Identity
PCS Table Breakdown
Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.
| Position | Designation | Value | Meaning |
|---|---|---|---|
| 1 | Section | X | New Technology |
| 2 | Body System | W | Anatomical Regions |
| 3 | Operation | 0 | Introduction |
| 4 | BodyPart | Q | Cranial Cavity and Brain |
| 5 | Approach | 3 | Percutaneous |
| 6 | Device/Substance/Technology | 1 | Eladocagene exuparvovec |
| 7 | Qualifier | 6 | New Technology Group 6 |
Code History
- 3E0Q3GC — Introduce Oth Therap Subst in Cran Cav/Brain, Perc
Questions About XW0Q316
Is XW0Q316 a billable code?
Yes. XW0Q316 is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Eladocagene exuparvovec into Cranial Cavity and Brain, Percutaneous Approach, New Technology Group 6 on inpatient claims from October 1, 2025 through September 30, 2026.
What do the characters in XW0Q316 mean?
XW0Q316 breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character Q is the BodyPart (Cranial Cavity and Brain); the 5th character 3 is the Approach (Percutaneous); the 6th character 1 is the Device/Substance/Technology (Eladocagene exuparvovec); the 7th character 6 is the Qualifier (New Technology Group 6).
What MS-DRG does XW0Q316 group to?
On an inpatient stay, Introduction of Eladocagene exuparvovec into Cranial Cavity and Brain, Percutaneous Approach, New Technology Group 6 maps to MS-DRGs 628, 629, 630, with relative weights from 1.4595 to 3.7268. The MS-DRG sets the fixed Medicare payment for the stay.
